Boehringer Ingelheim GmbH’s zongertinib enters the market as the first oral HER2-targeted therapy for patients with non-small ...

In less than two weeks, Setpoint Medical Inc. mastered the power serve with the first approval of a neuroimmune modulation device to manage rheumatoid arthritis, followed by a $25 million second ...

Experimental drugs that directly inhibit the NSD2 enzyme have shown potential as an effective strategy against hard-to-treat cancers, such as lung and pancreatic tumors driven by KRAS mutations. The ...

Ischemic stroke triggers a strong neuroinflammatory response, with microglial activation and neutrophil infiltration ...

Just two days after reporting the appointment of a new CEO, Instylla Inc. said it received a premarket approval from the U.S.

Although congenital aortic valve disease (AVD) is one of the most prevalent types of congenital heart disease, affecting 1% ...

Proteinqure Inc. has received regulatory clearances from the U.FDA and Health Canada to initiate a phase I trial of lead ...

Biopharma companies raised $34.89 billion through financings in the first seven months of 2025, including $5.66 billion in ...

Med-tech companies brought in $18.11 billion through financings in the first seven months of 2025, marking a modest rebound ...

In the tumor microenvironment, cancer cells activate various signaling pathways to promote their growth. This includes the ...

The Nipah virus (NiV) from the Henipavirus genus is a bat-borne zoonotic pathogen that causes encephalitis and acute ...

Quantumpharm Inc., known as Xtalpi Inc., announced receiving $51 million up front from a potential $5.99 billion deal with ...